Definium Therapeutics, Inc., was incorporated in 2010 under the laws of British Columbia. They are a late-stage clinical biopharmaceutical company developing new product candidates to treat brain health disorders. Their mission is to forge a new era of psychiatry by applying the rigors of science to psychedelics, with the goal of developing available treatments to unlock healing at scale. They are developing a series of innovative product candidates targeting neurotransmitter pathways that play a key role in brain health diseases. 

DFTX

DFTX Profile